Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Vertex Signs Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
Standard Uranium Provides Update on $3 Million Strategic Investment and Announces Extension to Closing Date of Private Placement
